TABLE 2

Comparisons of allele frequencies in the Norwegian sample of 1,644 type 2 diabetic and 1,879 control subjects

MarkerPosition (bp)Minor/major alleleMinor allele frequency
Allelic OR*
Case subjectsControl subjectsOR (95% CI)P
rs1884613−3925G/C0.1980.1811.17 (1.03–1.35)0.02
rs21449081377A/G0.1970.1781.21 (1.05–1.38)0.007
rs610371615290C/A0.3390.3381.03 (0.92–1.16)0.57
rs606572520675A/G0.3140.3160.99 (0.88–1.11)0.89
rs601733526485A/G0.4860.4671.06 (0.96–1.18)0.26
rs603158030941A/G0.2720.2800.96 (0.85–1.08)0.46
rs481283133920A/G0.1130.0971.21 (1.02–1.44)0.03
rs309237035763A/G0.4690.4820.93 (0.83–1.03)0.16
rs71724841265G/A0.0300.0320.96 (0.70–1.32)0.81
rs71724741444G/A0.3010.3130.93 (0.83–1.05)0.24
rs102858366421T/G0.3540.3580.98 (0.88–1.10)0.76
rs381824773140T/G0.3300.3470.92 (0.82–1.03)0.15
  • *

    * Calculations based on logistic regression with age, BMI, and sex as cofactors.

  • Position relative to start of the HNF4A P2 promotor (according to Goldenpath: hg17; dbSP: build 123).